Search Results 1781-1790 of 18794 for Relapse

1. Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL - Mayo Clinic

   Relapsed or refractory to hypomethylating agents; Acute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates for intensive AML ...

2. Clinical trials - Oncology (Medical)

   ... Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Rochester ... Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ...

3. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis - Mayo Clinic

   Known positivity for the FIP1L1-PDGFRA fusion (except for patients who demonstrated relapse or disease progression on prior imatinib therapy). Patients with ...

4. A Study to Evaluate the Safety and Effectiveness of IFX-1 in Add-on to Standard of Care in Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - Mayo Clinic

   New or relapsed GPA or MPA that require treatment with CYC or RTX plus GCs. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73 m^2. History of ...

5. Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma - Mayo Clinic

   Relapsed or refractory to prior standard treatment regimens; At least one site of measurable disease; Eastern Cooperative Oncology Group (ECOG) Performance ...

6. Hematology - Clinical trials

   Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND. Hypo ...

7. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma - Mayo Clinic

   For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biopsy-proven grade 1, 2 or 3A, FL or MZL, ECOG performance status 0 to 2, and have ...

8. Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic

   All of this points to the fact that targeting HER2 is a relevant strategy in gastrointestinal malignancies, including CRC . Looking specifically at the relapsed ...

9. Science Saturday: Quest to unmask an elusive immune cancer - Mayo Clinic News Network

   What's the most effective treatment for me? “Sometimes, the lymphoma could be controlled with chemotherapy, but other patients relapsed repeatedly. Why? We just ...

10. Using CAR-T cell therapy to treat patients with lymphoma and cardiomyopathy or cardiac metastasis saves lives - Mayo Clinic

    In recent years it's shown to be an effective treatment for selected patients with relapsed or refractory B-cell lymphomas. "CAR-T cells are engineered ...